RecruitingNCT05618002

Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients


Sponsor

Salem Anaesthesia Pain Clinic

Enrollment

150 participants

Start Date

Nov 8, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

Prospective observational crossover study of 150 consenting adult patients who are undergoing chronic pain management. For insomnia treatment, each patient ingests prescribed doses of Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data including pain score, sleep score, sleep duration, sleep medication type, and adverse effects. Each patient completes the diary for 3 continuous weeks. Pain is measured using the numeric pain rating scale. Sleep score is measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points is considered significant.


Eligibility

Min Age: 20 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Lemborexant for people with chronic insomnia and chronic pain. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years to 99 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLemborexant

For insomnia treatment, each patient ingests Lemborexant or Zopiclone or Clonidine on alternate nights. Each patient uses a special validated sleep diary to collect data.


Locations(1)

Salem Anaesthesia Pain Clinic

Surrey, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05618002


Related Trials